Exchange: OTC Sector: Healthcare Industry: Biotechnology
0.00% $0.0000
America/New_York / 9 feb 2024 @ 14:22
FUNDAMENTALS | |
---|---|
MarketCap: | 0.0001 mill |
EPS: | -0.0200 |
P/E: | 0 |
Earnings Date: | Jun 20, 2024 |
SharesOutstanding: | 64.93 mill |
Avg Daily Volume: | 0 mill |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/19 | 4/19 | 1/20 | 2/20 | 3/20 | 4/20 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | n/a | n/a | ||||
Debt | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 0 | sector: PE 29.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
N/A |
Company: PE 0 | industry: PE 136.10 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.0001 - 0.0001 ( +/- 0.00%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-03-31 | Jemapete Christopher J | Buy | 0 | |
2021-03-17 | Jemapete Christopher J | Buy | 200 000 | Common Stock |
2021-03-16 | Jemapete Christopher J | Buy | 300 000 | Common Stock |
2021-02-26 | Jemapete Christopher J | Sell | 0 | Common Stock |
2015-03-23 | Hutchison Murray H | Buy | 50 000 | Warrant to purchase Common Stock |
INSIDER POWER |
---|
0.00 |
Last 8 transactions |
Buy: 750 000 | Sell: 0 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.0000 (0.00% ) |
Volume | 0.0003 mill |
Avg. Vol. | 0 mill |
% of Avg. Vol | 0 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.